生命体征:2018年美国急性弛缓性脊髓炎监测
本报告更新2018年向CDC报告的急性弛缓性脊髓炎(AFM)病例的临床、实验室和结局数据。2018年共报告374例临床符合AFM的病例,其中233例(62%)为确诊病例,26例(7%)为可能病例,115例(31%)为非AFM病例。确诊病例中44%检出多种肠道病毒/鼻病毒类型。从肢体无力起病到标本采集间隔2至7天,到报告CDC间隔18至36天。识别导致AFM暴发的风险因素仍是公共卫生优先事项。
要点
- 2018年报告374例临床符合AFM病例,233例(62%)确诊,26例(7%)可能,115例(31%)非AFM。
- 确诊病例中44%检出多种肠道病毒/鼻病毒类型,主要见于呼吸道和粪便标本。
- 从肢体无力起病到报告CDC间隔18至36天,确诊和可能病例比非AFM病例报告更早。
核心结论
- 识别导致AFM暴发的风险因素仍是公共卫生优先事项。
- 及时识别症状体征、早期采集标本以及完整快速报告将加速公共卫生调查和研究,以阐明AFM近期流行病学并为治疗和预防建议提供依据。
研究设计与样本
- 对美国2018年起病且符合AFM临床标准(急性起病的肢体弛缓性无力)的病例,向CDC提交临床数据和标本,进行分类为确诊、可能或非AFM病例。
- 对符合临床标准的病例可用标本进行肠道病毒/鼻病毒(EV/RV)检测,并总结描述性分析、实验室结果及早期识别和报告指标。
主要发现
- 确诊、可能和非AFM病例的中位年龄分别为5.3岁、2.9岁和8.8岁。
- 确诊病例中44%检出多种EV/RV类型,主要见于呼吸道和粪便标本。
- 确诊病例中,从肢体无力起病到标本采集的间隔依标本类型为2至7天。
- 2018年从肢体无力起病到报告CDC的间隔为18至36天,确诊和可能病例比非AFM病例报告更早。
临床怎么用
- 临床医生应及时识别AFM体征和症状,早期采集标本并完整快速报告,以加速公共卫生调查和研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute flaccid myelitis (AFM), a serious paralytic illness, was first recognized as a distinct condition in 2014, when cases were reported concurrent with a large U.S. outbreak of severe respiratory illness caused by enterovirus D-68 (EV-D68). Since 2014, nationwide outbreaks of AFM have occurred every 2 years in the United States; the cause for the recent change in the epidemiology of AFM in the United States, including the occurrence of outbreaks and a biennial periodicity since 2014, is under investigation. This report updates clinical, laboratory, and outcome data for cases reported to CDC during 2018. METHODS: Clinical data and specimens from persons in the United States who met the clinical criterion for AFM (acute onset of flaccid limb weakness) with onset in 2018 were submitted to CDC for classification of the illnesses as confirmed, probable, or non-AFM cases. Enterovirus/rhinovirus (EV/RV) testing was performed on available specimens from persons meeting the clinical criterion. Descriptive analyses, laboratory results, and indicators of early recognition and reporting are summarized. RESULTS: From January through December 2018, among 374 reported cases of AFM, 233 (62%) (from 41 states) were classified as confirmed, 26 (7%) as probable, and 115 (31%) as non-AFM cases. Median ages of patients with confirmed, probable, and non-AFM cases were 5.3, 2.9, and 8.8 years, respectively. Laboratory testing identified multiple EV/RV types, primarily in respiratory and stool specimens, in 44% of confirmed cases. Among confirmed cases, the interval from onset of limb weakness until specimen collection ranged from 2 to 7 days, depending on specimen type. Interval from onset of limb weakness until reporting to CDC during 2018 ranged from 18 to 36 days, with confirmed and probable cases reported earlier than non-AFM cases. CONCLUSION: Identification of risk factors leading to outbreaks of AFM remains a public health priority. Prompt recognition of signs and symptoms, early specimen collection, and complete and rapid reporting will expedite public health investigations and research studies to elucidate the recent epidemiology of AFM and subsequently inform treatment and prevention recommendations.
引用
- Lopez A, Lee A, Guo A, et al. Vital Signs: Surveillance for Acute Flaccid Myelitis - United States, 2018. MMWR Morb Mortal Wkly Rep. 2019. PMID: 31295232. doi:10.15585/mmwr.mm6827e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。